NO2718434T3 - - Google Patents

Info

Publication number
NO2718434T3
NO2718434T3 NO12748354A NO12748354A NO2718434T3 NO 2718434 T3 NO2718434 T3 NO 2718434T3 NO 12748354 A NO12748354 A NO 12748354A NO 12748354 A NO12748354 A NO 12748354A NO 2718434 T3 NO2718434 T3 NO 2718434T3
Authority
NO
Norway
Application number
NO12748354A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2718434T3 publication Critical patent/NO2718434T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
NO12748354A 2011-08-10 2012-08-10 NO2718434T3 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521899P 2011-08-10 2011-08-10

Publications (1)

Publication Number Publication Date
NO2718434T3 true NO2718434T3 (no) 2018-08-25

Family

ID=46690751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12748354A NO2718434T3 (no) 2011-08-10 2012-08-10

Country Status (17)

Country Link
US (6) US9289473B2 (no)
EP (3) EP3400958B1 (no)
JP (5) JP6342802B2 (no)
CA (1) CA2882502A1 (no)
CY (1) CY1120877T1 (no)
DK (1) DK2718434T3 (no)
ES (2) ES2667418T3 (no)
HR (1) HRP20180687T1 (no)
HU (1) HUE037870T2 (no)
LT (1) LT2718434T (no)
NO (1) NO2718434T3 (no)
PL (2) PL2718434T3 (no)
PT (1) PT2718434T (no)
RS (1) RS57234B1 (no)
SI (1) SI2718434T1 (no)
TR (1) TR201806885T4 (no)
WO (1) WO2013023151A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2718434T3 (pl) 2011-08-10 2018-08-31 University Of Washington Through Its Center For Commercialization Kompozycje i sposoby leczenia choroby trzewnej
AU2014306716B2 (en) * 2013-08-14 2020-01-30 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
EP3302518A1 (en) 2015-06-08 2018-04-11 University of Washington Compositions and methods for treating celiac sprue disease
AU2017380106A1 (en) 2016-12-22 2019-07-04 Ew Nutrition Gmbh Stable protease variants
US20200383351A1 (en) * 2018-10-26 2020-12-10 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
MX2023004807A (es) 2020-10-30 2023-05-10 Univ Washington Composiciones y metodos para el tratamiento de la celiaquia.
WO2023147350A1 (en) 2022-01-26 2023-08-03 Digestiva, Inc. Blood glucose stabilizing methods and compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
ES2706911T3 (es) 2002-02-14 2019-04-01 Univ Leland Stanford Junior Tratamiento enzimático de alimentos para celíacos
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003294473A1 (en) 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
US8980254B2 (en) 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
PL2718434T3 (pl) * 2011-08-10 2018-08-31 University Of Washington Through Its Center For Commercialization Kompozycje i sposoby leczenia choroby trzewnej
CA2852365C (en) 2011-12-06 2021-01-26 Fondazione Istituto Insubrico Di Ricerca Per La Vita Proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus.
AU2014306716B2 (en) 2013-08-14 2020-01-30 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease

Also Published As

Publication number Publication date
DK2718434T3 (en) 2018-07-09
EP4023243A3 (en) 2022-09-14
US20160166656A1 (en) 2016-06-16
PT2718434T (pt) 2018-05-21
LT2718434T (lt) 2018-08-10
HRP20180687T1 (hr) 2018-06-15
CA2882502A1 (en) 2013-02-14
EP3400958B1 (en) 2021-08-04
JP6342802B2 (ja) 2018-06-13
JP2021094031A (ja) 2021-06-24
JP6502428B2 (ja) 2019-04-17
US20210085761A1 (en) 2021-03-25
HUE037870T2 (hu) 2018-09-28
US10149892B2 (en) 2018-12-11
WO2013023151A3 (en) 2013-07-18
US9707280B2 (en) 2017-07-18
EP2718434B1 (en) 2018-03-28
US20180185458A1 (en) 2018-07-05
ES2667418T3 (es) 2018-05-10
US10874720B2 (en) 2020-12-29
US9289473B2 (en) 2016-03-22
JP2019162107A (ja) 2019-09-26
SI2718434T1 (en) 2018-06-29
US20140178355A1 (en) 2014-06-26
US20170296633A1 (en) 2017-10-19
TR201806885T4 (tr) 2018-06-21
EP2718434A2 (en) 2014-04-16
RS57234B1 (sr) 2018-07-31
JP2014529399A (ja) 2014-11-13
PL3400958T3 (pl) 2022-01-03
PL2718434T3 (pl) 2018-08-31
US9925249B2 (en) 2018-03-27
JP2017221201A (ja) 2017-12-21
US20190083585A1 (en) 2019-03-21
WO2013023151A2 (en) 2013-02-14
JP2024028452A (ja) 2024-03-04
EP4023243A2 (en) 2022-07-06
CY1120877T1 (el) 2019-12-11
EP3400958A1 (en) 2018-11-14
ES2896489T3 (es) 2022-02-24

Similar Documents

Publication Publication Date Title
BR112013022641A2 (no)
BR112013031251A2 (no)
BR112013027245A2 (no)
BR112013024383A2 (no)
BR112013026905A2 (no)
BR112013023185A2 (no)
BR112013022995A2 (no)
BR112013026744A2 (no)
BR112013023927A2 (no)
BR112013027830A2 (no)
BR112013024365A2 (no)
BR112013028733A2 (no)
BR112013027121A2 (no)
BR112013027452A2 (no)
BR112013031556A2 (no)
BR112013026790A2 (no)
BR112013024588A2 (no)
BR112013032380A2 (no)
BR112013032377A2 (no)
BR112013032366A2 (no)
BR112013026895A2 (no)
BR112013027761A2 (no)
BR112013021637A2 (no)
BR112013027836A2 (no)
BR112013023266A2 (no)